within Pharmacolibrary.Drugs.ATC.N;

model N01AX14_1
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.48,
    Cl             = 1.49,
    adminDuration  = 600,
    adminMass      = 0.056,
    adminCount     = 1,
    Vd             = 0.709,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Esketamine is the S-enantiomer of ketamine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist. It is used as an anesthetic agent and, more recently, as an antidepressant for treatment-resistant depression. Esketamine nasal spray is approved for use in adults with treatment-resistant depression in combination with another oral antidepressant.</p><h4>Pharmacokinetics</h4><p>Intranasal administration in adults with treatment-resistant depression.</p><h4>References</h4><ol><li><p>Kurosawa, K, et al., &amp; Pérez-Ruixo, C (2023). Evaluation of Ethnicity Effect on Intranasal Esketamine Pharmacokinetics by Population Pharmacokinetic Modeling Using Data From a Japanese Phase 2b Study. <i>Clinical pharmacology in drug development</i> 12(4) 397–406. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1214&quot;>10.1002/cpdd.1214</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36560916/&quot;>https://pubmed.ncbi.nlm.nih.gov/36560916</a></p></li><li><p>Sanders, B, &amp; Brula, AQ (2021). Intranasal esketamine: From origins to future implications in treatment-resistant depression. <i>Journal of psychiatric research</i> 137 29–35. DOI:<a href=&quot;https://doi.org/10.1016/j.jpsychires.2021.02.020&quot;>10.1016/j.jpsychires.2021.02.020</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33647726/&quot;>https://pubmed.ncbi.nlm.nih.gov/33647726</a></p></li><li><p>Zannikos, P, et al., &amp; Singh, J (2023). Pharmacokinetics of Nasal Esketamine in Patients with Allergic Rhinitis with and Without Nasal Decongestant Pretreatment and in Healthy Subjects with and Without Nasal Corticosteroid Pretreatment. <i>Clinical pharmacokinetics</i> 62(9) 1315–1328. DOI:<a href=&quot;https://doi.org/10.1007/s40262-023-01273-z&quot;>10.1007/s40262-023-01273-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37402024/&quot;>https://pubmed.ncbi.nlm.nih.gov/37402024</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N01AX14_1;
